- Home
- App Analytics
- ePRO BI1403-0008
- ePRO BI1403-0008 Vs. Patient Connect by AiCure
ePRO BI1403-0008 vs Patient Connect by AiCure Usage & Stats
Boehringer Ingelheim ePRO BI1403-0008 is intended to collect patient reported outcomes relating to a clinical trial (BI Trial 1403-0008 – Brightline-1). Patients must be given accounts by a participating site in order to log in to the app.
- Apple App Store
- Free
- Medical
Store Rank
- -
Patient Connect is designed to support patients and volunteers as they participate in treatment, clinical trials and research activities. Benefits include:
**Guidance and Support**
Patient Connect provides helpful reminders for essential activities such as taking medication, answering questionnaires and upcoming visits. When it is time to take a dose, the app includes step-by-step guidance to ensure medication is taken as directed.
**Convenient Assessments**
The application enables participants to complete surveys and assessments about their health and treatment quickly and easily on their phone, allowing remote evaluation of progress between in-person visits.
**Engagement and Connection**
Patient Connect enables closer, simpler connections between participants and their care team, allowing healthcare providers to offer proactive communication and support between visits.
AiCure thanks all who contribute to the development of safe, effective treatments.
----
Please Note: This application is specifically designed for iPhones and is not yet validated for tablet devices such as iPads.
- Apple App Store
- Free
- Medical
Store Rank
- -
ePRO BI1403-0008 vs. Patient Connect by AiCure ranking comparison
Compare ePRO BI1403-0008 ranking trend in the past 28 days vs. Patient Connect by AiCure
Rank
No Data Available
ePRO BI1403-0008 vs. Patient Connect by AiCure ranking by country comparison
Compare ePRO BI1403-0008 ranking trend in the past 28 days vs. Patient Connect by AiCure
No Data to Display
Compare to any site with our free trial
ePRO BI1403-0008 VS.
Patient Connect by AiCure
December 25, 2024